

Prevention & Treatment of Hepatitis and Chronic Liver Disease

Seattle, WA May 4, 2024

Conference Location	Renaissance Hotel Seattle 515 Madison St Seattle, WA 98104	Phone: (206) 582-0300 https://www.marriott.com/en-us/hotels/seasm-renaissance-seattle-hotel/overview
Parking at the Conference	A discounted Self-Parking of \$17,00 per day has been arranged for all participants. Please bring your parking ticket to the seminar registration desk to receive this rate	
Driving Directions	Taking 1-5 North: Take Exit 164A for Dearborn Street toward James St and Madison Street. Keep left and merge onto 7 th Avenue. Turn Left on Madison Street toward the /Convention Center The hotel is at 6 th between Madison and Marion	
Seminar Agenda and Syllabus Information	Registration begins at 7:30 a.m. outside the South Room on the 3 rd Floor The Hepatitis and Chronic Liver Disease seminar is a paperless program. The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet or personal computer. Instructions to download the <i>App</i> will be provided. Wi-Fi will be available without charge.	
Pre-Program Activities	Pre-Lecture 1 – Viral Hepatitis –A summary for discovery and natural history of HCV 60 min Pre-Lecture 2 - End Stage Liver Disease: An overview of Treatment, Managing Complications chronic liver disease, cirrhosis, and the transplant process – 45 min	
7:30 am	<i>Registration and View Exhibits</i>	
8:00 am	Opening Comments and Pre-Test	
8:20 am	Advances in the Screening and Treatment of HCV <ul style="list-style-type: none"> • Updates on diagnostic approaches • Caring for At-risk populations – homeless, PWID, the incarcerated • Novel FDA Approved Direct Acting Anti-virals • Clinical Cases and Discussion 	
9:10 am	Hepatitis B: Epidemiology, History, Testing and Treatment <ul style="list-style-type: none"> • The epidemiology of the Hepatitis B infection • Efficacies and opportunities in HBV testing and vaccination • The efficacy of HBV Vaccination and Anti-viral therapies of HBV • HBV Re-activation and the Latest studies from EASL and AASLD 	
9:40 am	Delta Hepatitis and Hepatitis E Update <ul style="list-style-type: none"> • Global and US perspective on the growth of Delta Hepatitis • Lonafarnib and Bulevirtide of HDV: Benefits and potential hazards • Testing and surveillance approaches • Real world outcome studies on HDV and HEV 	
10:15 am	<i>Break and View exhibits</i>	
10:30 am	End Stage Liver Disease: Recap and Clinical Cases <ul style="list-style-type: none"> • A review of Pre-course lecture on end-stage liver disease • Complications of cirrhosis • Liver transplant in the era of DAA's • Clinical cases to illustrate HE. HRS and/or Thrombocytopenia 	

11:05 am	Hepatocellular Carcinoma(HCC) - Screening and Disease Progression <ul style="list-style-type: none"> • Screening diagnostic serum assays and imaging tests • Treatment and management options: Ablation, TACE and Surgery • New studies showing cost effectiveness of surveillance post SVR • PRIUS Study (MRI vs US) Abbreviated MRI • 2023 AASLD screening guidance for liver cancer and comments on biopsy for HCC
11:40 am	Hepatocellular Carcinoma: A case-based approach to New Systemic Treatment Options <ul style="list-style-type: none"> • Promising 1st and 2nd line therapies for liver cancer • New data on the benefit of downstaging • C chemotherapy regimens in development and testing Immunotherapy as the new MoA for HCC • Checkpoint inhibitors and VEGE inhibitors
12:20 pm	<i>Luncheon and Product Information Session</i>
12:55 pm	<i>Dessert and View Exhibits</i>
1:05 pm	Cholestatic Liver Disease: Primary Biliary Cholangitis and Primary Sclerosing Cholangitis <ul style="list-style-type: none"> • Epidemiology of PSC and Ursodiol and Antibiotic Treatments • Causes and Markers of PBC • Coping with the clinical features of PBC • Ursodeoxycholic Acid (UDCA) and Obeticholic Acid • Highlights of the ELATIVE study on elafibranor and the ENHANCE study on seladelpar
1:55 pm	Alcohol Associated Liver Disease <ul style="list-style-type: none"> • The growing prevalence of alcohol over-consumption and its impact on liver health • Alcohol consumption and malnutrition • Warning signs and intervention in alcohol-associated hepatitis • Promising therapeutic agents for AAH
2:30 pm	<ul style="list-style-type: none"> • <i>Break & View Exhibits</i>
2:45 pm	Steatotic Liver Disease: The new healthcare epidemic <ul style="list-style-type: none"> • New naming conventions for fatty liver disease: MASLD and MASH– what and why? • Epidemiology, Demographics and Diagnosis • Scoring, Staging and Management of Metabolic Liver Disease • The ‘unhealthy’ rise in MASLD in the US population and What can be done Treatment options for thrombocytopenia; including alternatives to platelet transfusion.
3:20 pm	MASH Treatments in Practice and in Development <ul style="list-style-type: none"> • Current therapies for NASH including Updates from AASLD and EASL • Lifestyle changes as a therapy • Drugs in clinical development for NASH – Semaglutide and Resmieron • MASH Diagnosis and Treatment case
4:00 pm	Closing Comments, Post-test and Wrap-Up Program adjourns at 4:15 pm
Post-program activities	Lecture 3 - Fluid Management, Ascites and Hepatorenal Syndrome 30 minutes Lecture 4 - Overcoming barriers to liver health in special populations - 30 minutes. Lecture 5 – AASLD Update – Highlights of the 2023 Liver Meeting – 30 minutes

Attendance Policies

Attendee Cancellation, Substitution, Refund

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

Recording and Photography

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

Guest Attendance

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues, and others.) are not permitted in the seminar areas.

Conference Modification or Cancellation

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course's schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **10.0 AMA PRA Category 1 Credit(s)**[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Information **Nurses** - This program has been approved by the Kentucky Board of Nursing for 12.0 continuing education credits through University of Louisville Hospital, provider number 4-0068-12-24-1383. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

Nurse Practitioners and Physician Assistants - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)[™] organizations accredited by ACCME.

**KRIS V. KOWDLEY, MD, FAASLD**

Dr. Kris Kowdley, Director of Liver Institute Northwest and clinical professor, Elson S. Floyd College of Medicine at Washington State University, received his B.S. in Biology and Anthropology as a member of the Dean's List at Columbia University, and his medical degree from Mount Sinai School of Medicine. He completed his internship and residency at Oregon Health Science University and a Fellowship in Gastroenterology and Hepatology at Tufts University School of Medicine.

Dr. Kowdley is internationally recognized as a clinician, educator, and researcher in liver disease. He has led several major international clinical trials of new treatments for hepatitis C, primary biliary cholangitis, primary sclerosing cholangitis and nonalcoholic steatohepatitis.

**ANNE LARSON, MD, FAASLD**

Anne Larson, MD is chief of UW Medicine's Northwest Hepatology Clinic and a UW Professor of Medicine.

Dr. Larson is a nationally recognized clinician, researcher and lecturer, the author of numerous peer-reviewed publications, and is recognized as a leader in the field of Hepatology. She believes that medical care should be a close collaboration between the physician and the patient. She enjoys caring for patients and creating long-term relationships that benefit their health.

Dr. Larson earned her M.D. from the UW. She is board certified in Gastroenterology and Transplant Hepatology. She is a fellow of the American Association for the Study of Liver Disease, American Gastroenterological Association and the American College of Physicians, and a member of the American Society of Transplantation.

Your Seminar Faculty**ANNE CROGHAN, MS, ARNP**

Anne Croghan is a nurse practitioner who specializes in hepatology, currently at UWMC—Northwest in Seattle. A native of western Washington, Anne has practiced hepatology at the VA, a specialty private practice group, and hospital-based hepatology clinics.

Her clinical practice includes patients in the evaluation and treatment of hepatitis C, hepatitis B, HCV/HIV co-infection, HBV/HIV co-infection, fatty liver disease, pre- and post-liver transplant patients, decompensated cirrhosis, and patients with hepatocellular carcinoma. She has also worked as an investigator on multiple clinical trials for viral hepatitis.

Ms. Croghan has also published articles in several recognized medical and nursing journals.